Cancer Treatment Reviews
Volume 31 , Pages S29-S37 , 2005

Gemcitabine in patients with ovarian cancer

References 

  1. Heintz APM, Odicino F, Maisonneuve P, et al. Carcinoma of the Ovary 25th FIGO Annual Report. Int J Gyn and Obstetr. 2003;83(Suppl 1):135–166
  2. McGuire WP, Ozols RF. Chemotherapy of Advanced Ovarian Cancer. Semin Oncol. 1998;25:340–348
  3. Junor EJ. The impact of specialist training for surgery in ovarian cancer. Int J Gynecol Cancer. 2000;10(Suppl 1):16–18
  4. submitted Du Bois A, Quinn M, Thigpen T, Vermorken J, Avall-Lundqvist E, Bookman M, et al. Consensus Statements on the Management of Ovarian Cancer. In: Final Document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004) Ann Oncol 2005. 2004;
  5. Poveda A. Ovarian Cancer Treatment: what is new. Int J Gynecol Cancer. 2003;13(Suppl 2):241–250
  6. Bookman MA. Developmental chemotherapy and management of recurrent ovarian cancer. J Clin Oncol. 2003;21:149s–167s
  7. Belpomme D, Krakowski I, Beauduin M, et al. Gemcitabine combined with cisplatin as first-line treatment in patients with epithelial ovarian cancer: a phase II study. Gynecologic Oncology. 2003;91(1):32–38
  8. Mar–Apr Bauknecht T, Hefti A, Morack G, et al. Gemcitabine combined with cisplatin as first-line treatment in patients 60 years or older with epithelial ovarian cancer: a phase II study. Int J Gynecol Cancer. 2003;13(2):130–137
  9. Nogue M, Cicera L, Arcusa A, et al. Phase II study of gemcitabine and cisplatin in women with ovarian cancer. Lancet. 1998;352:1571–1576
  10. Abstract 852 Ruiz GC, Alexander F, Rodriguez G, et al. Gemcitabine plus cisplatin as first-line therapy for advanced ovarian cancer. In: ASCO Annual Meeting. 2002;
  11. Abstract 1379 Hansen SW, Anderson H, Boman K, et al. Gemcitabine, carboplatin, and paclitaxel (GCP) as first-line treatment of ovarian cancer FIGO stages IIB-IV (meeting abstract). In: ASCO Annual Meeting. 1999;
  12. Poole ME, Bernard SA, Churchel MA, Weissler MC. A phase I study of gemcitabine and docetaxel for advanced stage solid tumors. Cancer Invest. 2003;21(3):350–354
  13. Abstract 857 Gupta S, Arora R, John S, et al. Gemcitabine, paclitaxel and cisplatin in chemotherapy naïve advanced ovarian cancer: results of a multi-center phase II study. In: ASCO Annual Meeting. 2002;
  14. in press Bookman MA Standard Treatment in Advanced Ovarian Cancer in 2005: the State of the Art. Int J Gynecol Cancer. 2005;
  15. for the GCIG Intergroup of 1AGO-OVAR (Germany), 2NSGO (Scandinavia), and 3GINECO (France) du Bois A1, Sehouli J1, Lund B2, Jolly F3, Huober J1, Jensen TS2, et al. Paclitaxel-carboplatin-gemcitabine (TCG) as first line treatment of ovarian cancer: A prospective multicentre phase II study (AGO-OVAR 8) followed by a prospectively randomized phase III GCIG Intergroup study (AGO-OVAR 9, GINECO-TCG, NSGO-OC-0102) comparing TCG with standard TC. in press In: Demographics and toxicity presented in Valencia at 5th International Symposium Advanced Ovarian Cancer. Valencia 25th February 2005. Int J Gynecol Cancer. 2005;
  16. Bookman MA. Extending the platinum-free interval in recurrent ovarian cancer. The role of topotecan in second-line therapy. The Oncologist. 1999;4:87–94
  17. Lund B, Hansen OP, Neijt JP, et al. Phase II study of gemcitabine in previously platinum-treated ovarian cancer patients. Anticancer Drugs. 1995;6(Suppl 6):61–62
  18. Shapiro JD, Millward MJ, Rischin D, et al. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol. 1996;63(1):89–93
  19. Frielander M, Millward MJ, Bell D, et al. A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. Ann Oncol. 1998;9(12):1343–1345
  20. Von Minckwitz G, Bauknecht T, Visseren-Grul CM, et al. Phase II study of gemcitabine in ovarian cancer. Ann Oncol. 1999;10(7):853–855
  21. Markman M, Webster K, Zanotti K, et al. Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer. Gynecol Oncol. 2003;90:593–596
  22. D'Agostino G, Amant F, Berteloot P, et al. Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer. Gynecol Oncol. 2003;88:266–269
  23. Bookman MA. Gemcitabine monotherapy in recurrent ovarian cancer: from the bench to the clinic. Int J Gynecol Cancer. 2005;15(Suppl 1):12–17
  24. Abstract 890 Jungnelius JU, Ridderheim M, Perren T, et al. Optimal sequence leads to improved dose delivery for gemcitabine (G)/paclitaxel (P) combination in recurrent ovarian cancer: a phase I study. In: ASCO Annual Meeting. 2002;
  25. Garcia AA, O'Meara A, Bahador A, et al. Phase II study of gemcitabine and weekly paclitaxel in recurrent platinum-resistant ovarian cancer. Gynecol Oncol. 2004;93(2):493–498
  26. Abstract 1951 Trudeau MG, Fox SB, Samson B, et al. Docetaxel and gemcitabine is an effective regimen in platinum-resistant ovarian cancer: a pilot study from the I.C.C.M.. In: ASCO Annual Meeting. 2003;
  27. D'Agostino G, Ferrandina G, Ludovisi M, et al. Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer. Br J Cancer. 2003;89:1180–1184
  28. Abstract 1551 Tobias D, Runowicz C, Mandeli J, et al. A phase I trial of gemcitabine and doxil for recurrent epithelial ovarian cancer. In: ASCO Annual Meeting. 2000;
  29. Greggi S, Salerno MG, D'Agostino G, et al. Topotecan and gemcitabine in platinum/paclitaxel-resistant ovarian cancer. Oncology. 2001;
  30. Sehouli J, Stengel D, Oskay G, et al. A new therapeutical approach: topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy with paclitaxel and platinum. J Obstet Gynaecol Res. 2003;29(3):123–131
  31. Nagourney RA, Brewer CA, Radecki S, et al. Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients. Gynecol Oncol. 2003;88(1):35–39
  32. Rose PG, Mossbruger K, Fusco N, et al. Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal cancer. Gynecol Oncol. 2003;88(1):17–21
  33. Abstract 1481 Safra T, Jeffers S, Groshen S, et al. Gemcitabine + amifostine + cisplatin (GAP) in pretreated epithelial ovarian cancer (meeting abstract). In: ASCO Annual Meeting. 1999;
  34. Velasco A, XXX M, Perez M, et al. Gemcitabine and cisplatin as treatment for patients with platinum resistant ovarian cancer and as consolidation treatment of patients with residual disease after first line chemotherapy. In: Proc Am Soc Clin Oncol. 20:2001;p. A2478a
  35. Kunkel LM, Evans SS, Dottino PR, et al. Cisplatin & gemcitabine in relapsed ovarian cancer. In: Proc Am Soc Clin Oncol. 17:1998;p. A1379
  36. Abstract 1594 Orlando M, Nadal J, Chacón R. Gemcitabine (G) and carboplatin (C) in patients (pts) with relapsed ovarian cancer (ROC): a phase I-II study. In: ASCO Annual Meeting. 2000;
  37. Soh KS. In: Proceedings International Gynecological Cancer Society (IGCS). 1999;
  38. Abstract 1395 Geertsen P, Hansen M, Stroyer I, et al. Combination chemotherapy with platinum, paclitaxel, and gemcitabine in patients with relapsed ovarian cancer (meeting abstract). In: ASCO Annual Meeting. 1999;
  39. The ICON and AGO collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003;361:2099–2106
  40. Gonzalez-Martin AJ, Calvo E, Bover I, et al. Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanõl de Investigación en Cáncer de Ovario) study. Ann Oncol. 2005;16:749–755
  41. Abstract 5005 Pfisterer J, Plante M, Vergote I, et al. Gemcitabine/carboplatin (GC) vs. carboplatin (C) in platinum-sensitive recurrent ovarian cancer (OVCA). Results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG. In: ASCO Annual Meeting. 2004;

PII: S0305-7372(05)80006-4

Cancer Treatment Reviews
Volume 31 , Pages S29-S37 , 2005

Article Tools